The first to establish an evidence base on which to build drug policies, Amanda Feilding has been at the forefront of drug policy reform for nearly 20 years.
Prohibition costs taxpayers billions each year, yet policies have failed to eliminate drug use and increased the risks and harms associated with drug taking. The Policy Programme provides a rigorous, independent review of current global drug policies, and is developing a scientific evidence-base on which to build balanced alternatives.
Each initiative, from our highly successful seminar series, “Society and Drugs: A Rational Perspective” to our international advisory work in Guatemala and Jamaica, brings together leading international scientists, politicians and other specialists to explore new regulatory models designed to diffuse drug-associated harms and protect public health.
Psilocybin for Depression
Type of publication